OPKO Q3 Revenue Up 16% as BioReference Sale Reshapes Reporting
OPK sits 73% above its 52-week low of $0.977.
Summary
Continuing operations revenue rose 16% to $65.4 million from $56.4 million, driven by $5.8 million of Lilly mazdutide royalty revenue, Rayaldee growth and international sales. Global Products swung to $6.0 million of segment operating income from a $1.2 million loss a year ago, but the Innovative Biotech segment's loss widened to $26.8 million as ModeX spending climbed. Net loss from continuing operations was $35.5 million, or $0.05 per share, versus $0.04 a year ago. BioReference is now booked as discontinued operations after the September 30 board approval of the Labcorp sale, and the company withdrew its services revenue and total cost guidance because of closing-timing uncertainty. Cash and restricted cash stood at $403.2 million, and OPKO bought back 7,050,000 shares for about $10.6 million in the quarter, leaving roughly $84.3 million on the $200 million authorization. The 4:30 p.m. ET call is the near-term event; the Labcorp deal still needs regulatory approval.
At the time of this announcement, OPK was trading at $1.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $0.98 to $1.81. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.